Page last updated: 2024-12-09

1-isonicotinoyl-4-(2-tolyl)thiosemicarbazide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-isonicotinoyl-4-(2-tolyl)thiosemicarbazide is a **heterocyclic organic compound** with the following structure:

* It consists of a **thiosemicarbazide** core, which is a molecule with a nitrogen-sulfur-carbon backbone,
* It has an **isonicotinoyl** group (a pyridine derivative) attached to one nitrogen atom, and
* It has a **2-tolyl** group (a substituted benzene) attached to another nitrogen atom.

This compound has shown promising activity in various research areas, especially in **medicinal chemistry and materials science**, due to its potential:

**1. Medicinal Chemistry:**

* **Antibacterial and antifungal properties:** Studies have shown that 1-isonicotinoyl-4-(2-tolyl)thiosemicarbazide exhibits significant antibacterial and antifungal activity against various strains of bacteria and fungi. This makes it a potential candidate for developing new antimicrobial agents.
* **Anti-inflammatory and analgesic activity:** Some studies suggest that the compound possesses anti-inflammatory and analgesic properties, potentially useful for treating inflammatory conditions and pain.
* **Anti-cancer activity:** Research indicates that the compound might have anti-cancer effects by inhibiting the growth and proliferation of certain cancer cells.

**2. Materials Science:**

* **Synthesis of metal complexes:** Due to the presence of sulfur and nitrogen atoms in its structure, 1-isonicotinoyl-4-(2-tolyl)thiosemicarbazide can coordinate with various metal ions, forming metal complexes. These complexes have potential applications in fields like catalysis, sensors, and electronic materials.

**3. Other Research Areas:**

* **Biochemistry:** The compound can be used as a ligand in various biological systems, potentially leading to the development of new probes for studying biological processes.

**Importance in Research:**

The compound's diverse biological activities and ability to form metal complexes make it an important subject for research. Researchers are actively investigating its potential applications in various fields, including:

* **Drug development:** Synthesizing new derivatives of the compound with improved pharmacokinetic properties and reduced side effects.
* **Material synthesis:** Designing new metal complexes with desired properties for specific applications in catalysis, sensors, and electronic materials.
* **Biological research:** Exploring its interaction with biological systems and its potential as a probe or therapeutic agent.

**It's important to note that while initial research shows promise, further investigations are needed to fully understand the compound's potential and safety profile before it can be used clinically or in commercial applications.**

1-isonicotinoyl-4-(2-tolyl)thiosemicarbazide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1534752
CHEMBL ID1399439
MeSH IDM0217086

Synonyms (21)

Synonym
AKOS002162050
REGID_FOR_CID_1534752
MLS000703468
smr000322876
1-(o-tolyl)-3-(pyridine-4-carbonylamino)thiourea
n-(2-methylphenyl)-2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide
1-(2-methylphenyl)-3-(pyridine-4-carbonylamino)thiourea
NCGC00246602-01
HMS2689O19
STL283896
1-ittsc
1-isonicotinoyl-4-(ortho-tolyl)thiosemicarbazide
1-isonicotinoyl-4-(2-tolyl)thiosemicarbazide
74270-70-5
2-isonicotinoyl-n-(o-tolyl)hydrazinecarbothioamide
F0331-0253
CHEMBL1399439
4-pyridinecarboxylicacid, 2-[[(2-methylphenyl)amino]thioxomethyl]hydrazide
DTXSID10225282
sr-01000005671
SR-01000005671-1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency14.12540.35487.935539.8107AID624170
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency0.63100.707912.194339.8107AID720542
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency7.94330.036619.637650.1187AID2100
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.00000.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1076034Antifungal activity against Candida tropicalis ATCC 66029 by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076025Antifungal activity against Candida sp. clinical isolate 12810 derived from blood by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076031Antifungal activity against Candida albicans ATCC 66027 by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076029Antifungal activity against Candida sp. clinical isolate 178 derived from high vaginal swabs by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076027Antifungal activity against Candida sp. clinical isolate 12341 derived from urine by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076032Antifungal activity against Candida sp. clinical isolate 13184 derived from high vaginal swabs by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076033Antifungal activity against Candida parapsilosis ATCC 22019 by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076024Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076030Antifungal activity against Candida sp. clinical isolate 11972 derived from high vaginal swabs by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076026Antifungal activity against Candida sp. clinical isolate 12485 derived from urine by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1076028Antifungal activity against Candida sp. clinical isolate 300 derived from urine by microbroth dilution method2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's5 (62.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.96 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]